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Summary
Our current understanding of the Wnt-dependent signaling pathways is mainly based on studies performed in a number
ofmodelorganisms including, Xenopus, Drosophilamelanogaster,Caenorhabditis elegansandmammals.Thesestudies
clearly indicate that the Wnt-dependent signaling pathways are conserved through evolution and control many events
during embryonic development. Wnt pathways have been shown to regulate cell proliferation, morphology, motility as
well as cell fate. The increasing interest of the scientiﬁc community, over the last decade, in the Wnt-dependent signaling
pathways is supported by the documented importance of these pathways in a broad range of physiological conditions and
disease states. For instance, it has been shown that inappropriate regulation and activation of these pathways is associated
with several pathological disorders including cancer, retinopathy, tetra-amelia and bone and cartilage disease such as
arthritis. In addition, several components of the Wnt-dependent signaling pathways appear to play important roles in
diseases such as Alzheimer’s disease, schizophrenia, bipolar disorder and in the emerging ﬁeld of stem cell research.
In this review, we wish to present a focused overview of the function of the Wnt-dependent signaling pathways and
their role in oncogenesis and cancer development. We also want to provide information on a selection of potential drug
targets within these pathways for oncology drug discovery, and summarize current data on approaches, including the
development of small-molecule inhibitors, that have shown relevant effects on the Wnt-dependent signaling pathways.
Introduction
The Wnt-dependent signaling pathways comprise several
branches whose differential activation depends on
the speciﬁcity of the Wnt ligands and Frizzled (Fzd)
isoforms involved, as well as the cellular context. These
pathways and their implication in several disease states
have attracted a lot of interest, both from academia
and the pharmaceutical industry, due mainly to the
fact that components of these pathways may act as264
good targets for drug discovery. In this review, we
will discuss the recent progress in understanding the
regulation of the Wnt-dependent signaling pathways
and their physiological role in human cancer, as well as
present some perspectives on the therapeutic potential
provided by targeted intervention of the Wnt pathways,
including the development of small molecule inhibitors
of the Wnt pathways in oncology drug discovery
research.
Overview of the Wnt-dependent signaling pathways
The Wnt-dependent signaling pathways encompass three
different molecular pathways downstream of Wnt/Fzd
interaction. The majority of published research on
Wnt signaling has been focused on the Wnt/β-catenin
pathway, which regulates cell fate determination by
regulating gene expression. The Wnt/β-catenin pathway
is also referred to as the “canonical” Wnt pathway. The
Wnt/Ca2+ and Wnt/polarity (also known as Planar Cell
Polarity,PCP)pathwaysareknownasthe“non-canonical
pathways”, and the identity of the components of both
these pathways has been unclear until recently. The
intracellular signal transduction cascades that have
been identiﬁed in each of these pathways are very
different from each other, but the common initial step
is the binding of a Wnt ligand to the cognate Fzd
receptor. Depending on the pathway which is activated,
the initiation signal will be transduced differently.
This decision most likely depends on which Wnt
ligand and FZD receptor are present, as well as the
cellular context. Nineteen Wnt ligands and 10 different
members of the Fzd seven-transmembrane receptor
family have been described in the human genome
(http://www.stanford.edu/∼rnusse/wntwindow.html).
Consequently, a large variety of responses could be
initiated from Wnt/Fzd interactions.
ThedifferentWntligandshavebeenclassiﬁedintotwo
functionalgroups.Theﬁrstgroup,referredtoastheproto-
oncogenic or transforming group (e.g., Wnt1, -3A, -8 and
-8B), induce a secondary axis in early Xenopus embryos
[1] and transform C57MG mammary epithelial cells [2,
3] when ectopically expressed. In general, this group can
activate the β-catenin pathway. The second group (e.g.,
Wnt4,-5Aand-11)donotelicitaxisduplicationinXeno-
pus embryos [1] and cannot transform C57MG cells [3].
However, these Wnts alter cell movements and reduce
cell adhesion when over-expressed in Xenopus embryos
[1, 4]. These Wnts can activate the non-canonical Wnt
pathways, as well as antagonize the activity of the trans-
forming Wnts [5]. This classiﬁcation is not exclusive, for
instance,Wnt5ahasbeenshowntoactivatenon-canonical
pathways,butwhenco-expressedwithFzd5,itcaninduce
axis duplication (canonical pathway) [6].
Fzd receptors can be classiﬁed into several groups
based on their basal signaling activity when ectopically
expressed in Xenopus. In this context, in the absence of
ectopic ligand, members of the Fzd family preferentially
activate either the β-catenin or the Ca2+ pathway [7]. As
showninFigure1,thereare4familiesofWntantagonists
that can be divided into twosub-groups according to their
mode of action. The ﬁrst group includes the secreted-
Frizzled related protein (sFRP) family, Wnt-inhibitory
factor-1 (WIF-1), and Cerberus. They inhibit Wnt sig-
naling by direct binding to Wnt molecules. The second
group, consisting of the Dickkopf (DKK) family, inhibits
Wnt signaling by binding to the LRP5/LRP6 component
of the Wnt receptor complex [8].
The Wnt/β-catenin pathway has been extensively
studied in different vertebrate and invertebrate model
systems and it was shown that β-catenin is the central
molecule. Thepathway requires anadditional single-pass
transmembrane protein, known as LRP5 or LRP6 from
the low-density-lipoprotein (LDL) receptor family,
to function as an obligate co-receptor of the seven-
transmembrane Fzd receptors for transducing the Wnt
signal [9–11]. The amino-termini of LRP and FZD were
reportedtoassociateonlyinthepresenceofWnt[12],im-
plying that Wnt ligands form a trimeric complex with an
LRPandFZDreceptor.However,itwasrecentlyreported
thatLRPsactivatetheWnt/β-cateninpathwaybybinding
to Axin in a disheveled (Dvl) independent manner, while
Fzd receptors transduce Wnt signals through Dvl to
stabilize β-catenin [13]. It is thus possible that Wnt
proteins form separate complexes with Fzd receptors and
LRPs, transducing the signals separately, but converging
downstream in the Wnt/β-catenin pathway. The current
model of Wnt/β-catenin activation starts with the binding
of Wnt to a receptor complex encompassing a Fzd recep-
tor and LRP co-receptor. The biochemical mechanisms
by which the binding of the Wnt ligand to its cognate
Fzd receptor elicits signal transduction within the cell are
poorly characterized. After Wnt binding, Dvl is phospho-
rylated and through its association with Axin, prevents
glycogen synthase kinase 3β (GSK3β) and casein kinase
1α (CK1α) from phosphorylating critical substrates,
including β-catenin. Phosphorylation of β-catenin
at the N-terminus by CK1α and GSK3β is essential
for its targeted degradation [14]. Non-phosphorylated
β-catenin escapes recognition by β-Transducin repeat
Containing Protein (β-TrCP), a component of an E3
ubiquitin ligase complex, thereby avoiding degradation.
This non-phosphorylated form of β-catenin is then
able to localize to the nucleus [15], form a complex
with Tcf/Lef transcription factors and co-activators
such as (CREB Binding Protein, CBP) [16, 17] and
induce the expression of downstream target genes (see
http://www.stanford.edu/∼rnusse/wntwindow.html). Al-265
Figure 1. Schematic overview of the Wnt signaling pathways. In the absence of active Wnt (left) β-catenin is degraded and Tcf/Lef transcription
factors act as repressor. When a Wnt signal is present (right) β-catenin accumulates in the cytoplasm, localizes then to the nucleus, and activates
transcription together with Tcf/Lef transcription factors.
though Tcf/Lef directly bind to DNA through their HMG
domains, they are incapable of independently activating
gene transcription [18]. β-catenin is the additional
co-activator required for transcriptional activation [19]
together with other co-activators such as CBP [20]. In the
absenceofaWnt/Fzdsignal,β-cateninisphosphorylated
by GSK3β and CK1α, subsequently ubiquinated and
rapidly degraded by the proteasome. β-catenin levels
will not be able to accumulate in the nucleus, and
Tcf/Lef proteins will act as transcriptional repressor,
mediated through the interaction of Tcf/Lef with at least
two different gene products, Groucho and C-terminal
Binding Protein (CtBP) [17, 21–23].
Signaling through the Wnt/Ca2+ pathway is inde-
pendent of β-catenin. The Wnt/Ca2+ pathway regu-
lates cell adhesion and motility [24], and is mediated
through release of intracellular Ca2+ upon Wnt stimula-
tion, and involves activation of protein kinase C (PKC)
and calcium/calmodulin-dependent kinase II (CamKII)
[25–27], leading to the regulation of the Ca2+-responsive
transcription factor NF-AT [28, 29]. Wnt-5a was the ﬁrst
Wntligandidentiﬁedtosignaldownthispathwayandwas
shown to require coupling to G-proteins [26, 30]. Inter-
estingly, the Wnt/Ca2+ pathway activated by Wnt-5a, an-
tagonizes the Wnt/β-catenin pathway [1, 5, 29, 31]. One
mechanism of inhibition is via CamKII. CamKII will ac-
tivate the MAP kinase-related Nemo-like kinase (NLK),
whichwillphosphorylateTcftranscriptionfactors,which
will prevent β-catenin/Tcf-mediated transcription [31,
32]. In addition, PKC, activated by the Wnt/Ca2+ path-
way,hasbeenshowntoblocktheWnt/β-cateninpathway
by phosphorylating Dvl [33].
In the Wnt/polarity pathway, referred to as the Planar
CellPolarity(PCP)pathwayinDrosophila,Fzdfunctions
to establish asymmetric cell polarities and coordinate cell
shape changes and cellular movement. Much of the cur-
rent understanding of the molecules governing this path-
way has come from studies in Drosophila as several clear
effects of the PCP pathway, such as hair follicle and bris-
tleorientation,canbereadilyassessedinthisorganism.In
addition, the existence of mutant genes that affect planar
polarized structures in Drosophila have been exploited to
study the processes governing PCP. In this pathway, Fzd
regulates the activity of the small GTPases Rho and Rac
through different domains of Dvl. Rho and Rac, in turn,
regulate the activity of Rock and Jun N-terminal Kinase266
(JNK) respectively [34–36]. PCP was recently demon-
strated in a mammalian system—mammalian cochlea—
inwhichthePCPpathwayinitiatedbyWnt7agovernsthe
unidirectional orientation of sensory hair cells necessary
for unimpaired hearing [37]. The PCP pathway is also
involved in regulating cell polarization during vertebrate
gastrulationmovements[5,36,38,39]inwhichactivation
ofbothRhoandRacarerequiredforconvergentextension
[36]. Thus, although differences exist between vertebrate
and invertebrate pathways, the core components of the
pathway are conserved through evolution.
Implication of Wnt-dependent signaling pathways
in Oncology
TheﬁrstWnt(atthattimestillknownasint1)wasdiscov-
ered more than 20 years ago [40], as a proto-oncogene in
mammary tumors activated by integration of the mouse
mammary tumor virus. Since then, more studies have
linked the Wnt-dependent signaling pathways to oncoge-
nesis and cancer development. While the Wnt pathways
have been the focus of a great deal of experimentation
with increasing number of reports and publications every
year, a number of questions still remain to be answered.
As the downstream components were identiﬁed, more
studies have found evidence linking the different compo-
nentsofthesepathwaystocancer[41–44]aswellasother
indications (Table 1).
Deﬁnitive proof of the involvement of Wnts in hu-
man cancer has been lacking for years. There have been
numerous reports describing either over-expression or,
sometimes,under-expressionofWntgenesinhumancan-
cers, but mRNA expression levels can at best be correla-
tive. A transgenic mouse model has recently shown that
tumor growth is dependent on Wnt-1 expression [45].
Studies of Wnt expression in human breast tumors have
tended to support a role for Wnt signaling in the develop-
ment of breast cancer [46–50]. Wnt5a signaling has also
been shown to directly affect cell motility and invasion
of metastatic melanoma. Blocking this pathway using an-
tibodies to Fzd5, a receptor for Wnt5a, was shown to
inhibit PKC activity and cellular invasion. Furthermore,
Wnt5a expression in human melanoma biopsies directly
correlated with increasing tumor grade [51]. More com-
pelling evidence, such as ampliﬁcation, rearrangements,
or mutation of genes encoding Wnt ligands or receptors
has thus far not been identiﬁed. Chen and colleagues
showed that cells expressing Wnt1 were resistant to can-
cer therapy mediated apoptosis. Wnt1 signaling inhibited
cytochrome c release and the subsequent caspase-9 acti-
vation that was induced by chemotherapeutic drugs, in-
cluding both vincristine and vinblastine. Further research
showed that Wnt1 signaling inhibited apoptosis by acti-
vating β-catenin/Tcf mediated transcription [52]. It was
Table 1. Wnt-dependent signaling pathway components involved in





Wnt(s) Cancer Elevated [47, 186]
Wnt5a Cancer/metastasis Elevated [51]
sFRP(s) Cancer Variable [55, 56, 59]
WIF-1 Cancer Reduced [63]
LRP5 Osteosarcoma Elevated [68]
Fzd(s) Cancer Elevated [187]
β-catenin Cancer Gain of function [41]
APC Cancer Loss of function/
reduced
[78, 79]
Axin Cancer Loss of function [83]
GSK3β Cancer Deregulated [188, 189]
Wnt1 Schizophrenia Elevated [190]
GSK3β Schizophrenia Variable [191]










sFRP3 Osteoarthritis SNP/reduced [195]
LRP5 Low bone mass Loss of function [69]
LRP5 High bone mass Gain of function [70, 196]
Wnt3 Tetra-amelia Loss of function [197]
Fzd4 FEVR Loss of function [198]
LRP5 FEVR Loss of function [199]
Wnt4 Intersex Variable [200, 201]
APC: adenomatous polyposis coli; FEVR: familial exudative vitreo-
retinopathy;Fzd:Frizzled;GSK3β:glycogensynthasekinase3β;LRP:
LDL-receptor-related protein; sFRP: secreted Frizzled related protein;
SNP: single nucleotide polymorphism; WIF: Wnt inhibitory factor.
recently demonstrated that inhibition of Wnt2 mediated
signaling induced apoptosis in both malignant melanoma
cells and non-small-cell lung cancer cells [53, 54]. These
studies show that activation of the β-catenin/Tcf signal-
ing pathway by Wnt ligands not only provides a growth
advantage to cancer cells, but also signiﬁcantly affects
theclinical outcome by inhibiting chemotherapy-induced
apoptosis. Blocking Wnt signaling, for instance with a
monoclonal antibody or development of small molecules
can be useful to inhibit the Wnt/β-catenin signaling path-
way for treatment of cancer patients and may improve
the efﬁcacy of chemotherapy by enhancing apoptosis in
cancer cells.267
The Wnt signaling pathway antagonists have also been
studied extensively in developmental studies and their
involvement in oncogenesis was recently demonstrated.
Loss of expression of sFRP1 was reported in bladder
cancer [55], and down-regulation of family members has
been reported in cervical carcinomas [56], breast can-
cers [57], and gastric cancers [58], whilst the promoters
of several sFRP family members have been shown to
be hypermethylated in colorectal tumors [59–61]. WIF-1
downregulation was recently reported by Wissman and
colleagues in several cancer types including lung cancer
[62]anditwasshownthatWIF-1wasfrequentlysilenced
by hypermethylation of its promoter in lung cancer cell
lines as well as in fresh lung cancer tissues [63].
Both Fzd and its co-receptor LRP have also been im-
plicatedincarcinogenesisalthoughclearproofislacking.
Expression studies for the Fzd genes have indicated that
aberrant expression of these genes is involved in human
cancer [7, 46, 49, 58, 64–67], and LRP5 was identiﬁed as
a possible marker for disease progression in high-grade
osteosarcoma [68]. The presence of LRP5 correlated sig-
niﬁcantly with tumor metastasis and the chondroblastic
subtype of osteosarcoma. Patients with LRP5 expression
in the tumor showed decreased event free survival. In ad-
dition, mutations in LRP5 have been linked to diseases
with signiﬁcant skeletal abnormalities [69, 70].
The most compelling evidence implicating the Wnt
signaling pathway in carcinogenesis is the observation
that β-catenin functions as an oncogene in different can-
cers, while APC and Axin act as tumor suppressor genes.
Mutations in the β-catenin gene, affecting the amino-
terminal region of the protein, increase the stability of the
β-cateningene.Thesemutationsaffectspeciﬁcserineand
threonine residues, which are sites for priming by CK1
(Ser 45) and further phosphorylation by GSK3β (Ser 33,
37 and Thr 41) and are essential for the recognition by
β-TrCP,markingβ-cateninfordegradation[71].Somatic
mutations in the amino-terminal region of the β-catenin
gene have been described in a wide variety of human
cancers, including colorectal, endometrial, ovarian, pan-
creatic, hepatocellular, prostate, gastric and thyroid car-
cinoma, desmoid tumor, hepatoblastoma, medulloblas-
toma, melanoma, pilomatricoma, squamous cell carci-
noma of the head and neck, and Wilms’ tumor [41].
Both APC and Axin have a regulatory function in the
Wnt signaling pathway, and both have been shown to be
critical for the down-regulation of β-catenin [72–74]. It
has been proposed that Axin and APC facilitate the phos-
phorylation of β-catenin by GSK3β [75–76]. About 80%
of sporadic colorectal carcinomas and cell lines derived
from these tumors harbor mutations in the APC gene
[77, 78], Most of them are nonsense or frame shift muta-
tions leading to a truncated APC protein. About 60% of
these mutations are clustered in a 700 bp “mutation clus-
ter region” corresponding to the β-catenin/Axin-binding
domain. Apart from APC mutations, hypermethylation
of the APC promoter at CpG sites was also detected in
colorectalcancer[79],whichmaythusconstituteanalter-
native mechanism for APC gene inactivation. Beside the





mutations in colorectal cancers makes identiﬁcation of
these mutations a worthwhile strategy for diagnosis and
early detection of colorectal carcinomas. Axin has also
been shown to be mutated in hepatocellular cancer and
the derivative cell lines [83]. All of the mutations were
predicted to truncate the Axin protein in a manner that
eliminated the β-catenin binding sites, and thus prevent-
ing Axin from facilitating β-catenin phosphorylation and
degradation.
Finally, all previously discussed aberrations and mu-
tations in components of the Wnt-dependent signaling
pathways lead to activation of Tcf/Lef target genes by
β-catenin. A considerable number of target genes have
been identiﬁed (see Wnt homepage for a complete list)
andplayaroleindevelopmentandtumorigenesis.Several
of the target genes have functions in cell cycle, apopto-
sis, proliferation, transcription and are involved in tumor
progression. The ﬁrst identiﬁed target genes were c-Myc
and cyclin D1 [84, 85] through which Wnt signaling may
stimulate progression through the cell cycle. Other tar-
get genes that have been identiﬁed include, for instance,
vascular endothelial growth factor (VEGF), Wnt-1 in-
duced secreted protein 1 (WISP-1), Bone morphogenetic
protein-4 (BMP-4), matrix metalloproteinase (MMP) 7
and26.Thelistofdownstreamtargetgeneswillundoubt-
edly be extended and it will be interesting to elucidate the
relevance of these genes for human cancers.
As discussed, many genes in this pathway have been
implicated in neoplasia through mutations (APC, Axin,
β-catenin), and several other components through up-
or downregulated expression. However, variations in ex-
pression levels (up- and downregulation) are also found
in normal cells at different stages of development. Since
the Wnt signaling pathway is crucial for normal develop-
ment, the expression level of the different genes in adult
tissues can be considered as relevant for cancer research.
With the advent of high-throughput methods that evalu-
ate gene-expression in tumors [86–88], the discovery of
genesthataredifferentiallyexpressedhasbeenincreasing
exponentially. The information gained from these studies
has proven promising for the development of diagnos-
tic assays, particularly for prognosis, but the utility of a
gene as a cancer diagnostic does not necessarily reﬂect a
causative role in the process [89]. In the absence of muta-268
tional evidence, functional evidence obtained from stud-
ies in vitro or in non-human species in vivo must be used.
Levelsofgeneexpressionarethusunreliableindicatorsof
causation because disturbance of any network invariably
leads to a multitude of such changes only peripherally
related to the phenotype [90]. Taken together, it is appar-
ent that aberrant Wnt signaling can cause cancer and that
tumor promotion by this pathway can proceed through
different genetic defects that occur at several stages of
this pathway. Many different types of cancer, in different
tissues, have been linked to alterations in the Wnt signal-
ing pathway and it is thus not surprising that oncology is
the main disease area where antagonists of this pathway
could be of use.
Existing therapies with non-speciﬁc effects
on Wnt-dependent signaling pathways
As a result of all the evidence implicating Wnt signaling
in the pathophysiology of many human diseases, includ-
ing cancer, interest in the development of Wnt signaling
inhibitors has increased substantially. Different compo-
nents of these signaling pathways can be regarded as use-
ful targets in preventing and treating cancer, and several
therapeutic approaches currently being exploited may al-
ready be linked to Wnt pathways, although their actual
mechanism of action remain unclear. The development
of new targeted anticancer agents is based on the premise
thatthedrugmodulates aspeciﬁc molecular target.These
targets may be critical to cancer cell survival or may be a
regulatory pathway not used in normal cells. In the next
sections, we will discuss a number of therapies that have
a non-speciﬁc effect on the Wnt signaling pathways.
Non-Steroidal Anti-Inﬂammatory Drugs (NSAIDs)—
such as aspirin, indomethacin and sulindac—have been
demonstrated to act as anti-tumor agents [91, 92]. Reg-
ular use of NSAIDs is shown to be associated with a
reduced incidence of some cancers including breast and
colorectalcarcinomas.Epidemiologicalstudieshavedoc-
umented a decreased risk of colorectal cancer deaths as-
sociated with use of aspirin. Combined case-control data,
including over 30,000 colorectal cancer cases, indicated
a 45% reduction in the risk of developing colorectal can-
cer in subjects taking NSAIDs [93]. In individuals with
familial adenomatous polyposis (FAP), an inherited pre-
disposition to multiple colorectal polyps (due to a mu-
tation in APC), sulindac was shown to reduce both size
and number of colorectal polyps [94]. Likewise, other
NSAIDs have proven to be effective in the prevention of
intestinal tumorigenesis in mouse models of FAP [95].
Studies from hereditary and sporadic colorectal cancer
patients suggest that NSAIDs may interfere with the ini-
tiatingstepsofcarcinogenesis;i.e.,disturbancewithinthe
canonical Wnt signaling pathway. It was shown that both
aspirin and indomethacin attenuated the transcription of
β-catenin/Tcf-responsive genes by modulating Tcf activ-
ity without disrupting β-catenin/Tcf complex formation
[96]. After further exploration of this mechanism, it was
found that the reduced signaling activity of β-catenin in
responsetoNSAIDswasaresultofitsenhancedphospho-
rylation [97]. Phosphorylation of amino-terminal Ser/Thr
residues of β-catenin increased in response to aspirin and
indomethacin in a time-dependent manner [97]. Another
mechanism was shown by Nath et al. who demonstrated
that aspirin inhibited β-catenin/Tcf signaling in colon
cancer cells by disrupting nuclear β-catenin/Tcf [98].
This effect occurred far below the aspirin concentrations
required to inhibit cell growth, and may be a critical early
event in the chemopreventive activity of aspirin against
colon cancer. These results have been conﬁrmed by Boon
et al. who provided in vitro and in vivo evidence that nu-
clear β-catenin localization and β-catenin/Tcf regulated
transcription of target genes can be inhibited by sulindac
[99]. In different experimental setups in vitro, sulindac
also suppressed the formation of foci [100]. A recent
study has shed more light on the effects of NSAIDs on β-
catenin protein levels and β-catenin-related transcription
in human colorectal cancer cells. Gardner et al. studied
a panel of NSAIDs (indomethacin, diclofenac, sulindac
sulphide and sulphone, rofecoxib) on SW480 human col-




are attributed to inhibition of prostaglandin synthesis by
inactivation of cyclooxygenase 1 and 2 (COX-1 and 2)
[96, 102]. The above mentioned studies demonstrate that
COX-independent effects might be related to inhibition
of Wnt signaling, since there is a clear link between
the effects of NSAIDs as chemopreventive agents and
β-catenin/Tcf activity [96]. New selective inhibitors of
COX-2 (celecoxib and rofecoxib) are currently licensed
for use in the treatment of arthritis and more recently
in the chemoprevention of FAP [103]. Cardiovascular
safety doubts recently put this class of compounds in
the spotlight, and even led to the withdrawal of rofecoxib
(Vioxx
R  ).
Exisulind (AptosynTM) is the lead compound of a new
category of targeted anticancer agents—Selective Apop-
toticAnti-NeoplasticDrugs(SAANDs)—andisanoxida-
tive metabolite of the NSAID sulindac. Since exisulind
lacks the cyclooxygenase inhibitory activity characteris-
tic of NSAIDs, it is not an NSAID. Exisulind and analogs
are inhibitors of cyclic GMP phosphodiesterases (PDE)
and have been shown to increase kinase activity and in-
duce the expression of protein kinase G (PKG). The an-
tineoplastic effect of Exisulind appears to be the result of269
PKG activation which leads to multiple downstream ef-
fects culminating in apoptosis [104]. Activated PKG has
been shown to phosphorylate β-catenin at its C-terminal
domain, and to cause proteasome-dependent degradation
of β-catenin, independent of APC and GSK3β. As men-
tionedbefore,twopoolsofβ-cateninexist,oneassociated
with E-cadherin at the cell membrane, and a soluble one
in the cytoplasm [105]. In the absence of Wnt, levels of
β-catenin in the cytoplasmic pool are low due to targeted
degradation of β-catenin. It has been however shown that
β-catenin from the 2 pools can be exchanged, and that
thisexchangeisstronglyaffectedincellsthatcontainmu-
tations in APC [106]. In cells with intact Wnt signaling,
exisulinddidnotaffectβ-cateninlevels[107].Sincemost
β-catenin is then found in bound form (to E-cadherin),
phosphorylation by PKG may be prevented. In cell lines
expressing APC or β-catenin mutations, in which β-
catenin cannot be phosphorylated (N-terminal), exisulind
was shown to induce cell death. Exisulind and analogs
provide a potentially superior approach to circumvent the
molecular defects of the Wnt signaling pathway and to
treat cancers with such defects. Preclinical data evaluat-
ing SAANDs in combination with various chemotherapy
drugs indicated additive or synergistic antineoplastic ef-
fects. In clinical studies, exisulind prevented colorectal
polyp formation in patients with FAP over a 24 month
period [104]. Although exisulind has highly promising
features, it did not meet its end point in a Phase III clin-
ical trial for chemoprevention in FAP and has not been
approvedbytheFDA.However,itprovedhighlyeffective
forpolyp treatment withstatisticalsigniﬁcance inboth an
FAPcrossoverstudyandalargesporadicpolyptrial[107].
Vitamin A derivatives (retinoids) are potent regulators
of cell proliferation and differentiation. Retinoids have
been shown to inhibit the function of the oncogenic AP-1
and β-catenin/Tcf pathways as well as stabilize compo-
nents of the adherens junctions [108, 109]. Xiao et al.
showed that retinoid X receptor (RXR) agonists induced
degradation of β-catenin and RXRα and repressed β-
catenin-mediated transcription [110]. In in vivo experi-
ments,itwasshownthatβ-catenininteractedwithRXRα
in the absence of ligand, and that RXR agonists en-
hancedtheinteraction,suggestingthatRXRinteractswith
β-catenin in a retinoid-dependent manner, and thereby
reducing β-catenin/Tcf regulated transcription. Since a
chemopreventive activity by retinoic acid (RA) has been
demonstratedinratcolon,Mollersenetal.studieddietary
supplementation with all-trans RA in Min/+ mice [111].
In these Min/+ mice, which harbour a germline muta-
tion in the tumor suppressor gene APC, they surprisingly
showed that dietary RA signiﬁcantly stimulated both the
formation and growth of small intestinal tumors. Al-
thoughcontradictory,theseresultssuggestapotentialrole
for retinoids in the regulation of β-catenin turnover and
related biological events. Both RA and vitamin D have
been shown to have growth-inhibitory effects on colonic
epithelial cells. For these reasons, both compounds have
been suggested as potential candidates for chemopreven-
tion of colorectal cancer. In the case of RA, its receptor
is thought to compete with β-catenin for a common bind-
ing site on Tcf4. Vitamin D has been shown in breast
carcinoma cells to increase cadherin expression, thereby
decreasing cytosolic β-catenin and down-regulating β-
catenin signaling by a second route [112].
Endostatin (ES) is a fragment of collagen XVIII that
possesses anti-angiogenic activity. There is growing ev-
idence that anti-angiogenic drugs, like ES, will improve
futuretherapiesofdiseaseslikecancer,rheumatoidarthri-
tis and ocular neovascularization.
In a recent paper, ES was described as a potential in-
hibitor of Wnt signaling [113]. To gain insight into ES-
mediated signaling, they studied the effects of ES RNA
on Xenopus embryogenesis and observed developmen-
tal abnormalities consistent with impaired Wnt signaling.
ES RNA blocked the axis duplication normally induced
by β-catenin, partially suppressed Wnt-dependent tran-
scription, and stimulated degradation of both wild-type
and stabilized (degradation resistant through N-terminal
mutations) forms of β-catenin. They found that ES used
a pathway independent of the Siah1 protein in targeting
β-catenin for proteasome-mediated degradation. These
data were replicated in endothelial cells and also in hu-
man DLD-1 colon carcinoma cells that contain a mutated
APC gene [113]. Though high levels of ES were used in
both Xenopus and endothelial cell studies and the effects
on β-catenin signaling were modest, these data argue that
at pharmacological concentrations ES may impinge on
Wnt signaling and promote β-catenin degradation.
Curcumin (diferuloylmethane) is a natural plant prod-
uct,andhasbeenshowntoexhibitchemopreventiveactiv-
ity [114]. Since current cancer treatments such as radio-
and chemotherapy are associated with severe side-effects
and offer no ﬁrm expectation of a cure, there is a con-
stant need for the investigation of other potentially useful
options to prevent cancer. One of the most widely in-
vestigated approaches in cancer chemoprevention uses
natural agents to reverse or inhibit the malignant transfor-
mation of cancer cells and to prevent invasion and metas-
tasis.ItwaspreviouslyshownthatCurcuminimpairsboth
Wnt signaling and cell-cell adhesion pathways, resulting
in G(2)/M phase arrest and apoptosis although the ex-
act mechanism remained unknown [115]. A more recent
study showed that the reduced β-catenin/Tcf transcrip-
tionalactivitywasduetodecreasednuclearβ-cateninand
Tcf4 [116]. Further studies are undoubtedly necessary to
elucidate the mechanism(s) involved. Because Curcumin
has been shown to intervene in several pathways with a
high-level of safety and no toxicity, it has been proposed270
to be a wide-spectrum chemopreventive agent for cancer
[117—119].
Folic acid may have a chemopreventive role in colon
carcinogenesis, although the mechanism(s) of action
is poorly understood. It has been shown that folic acid
inhibited cell proliferation and EGF-receptor (EGFR)
activation in colon cancer cells [120, 121]. This effect
was associated with a concomitant reduction in nuclear
translocation of β-catenin [120]. Since the possible
role of folic acid as an inhibitor of Wnt signaling has
only recently been proposed more research would be
necessary to understand the mechanism.
HDAC inhibitors The recruitment of histone acetyl-
transferases (HATs) and histone deacetylases (HDACs)
is considered to be a key element in the dynamic regula-
tion of many genes regulating cell proliferation and dif-
ferentiation during normal development and carcinogen-
esis [122]. HDACs are usually subunits of multiprotein
complexes and HDAC inhibitors are considered as very
promising drug candidates for the treatment of leukemia,
and various other forms of cancer [123–125]. In theory,
inhibitors of HDAC may enable the re-expression of re-
pressed regulatory genes in cancer cells and reverse the
malignant phenotype. In the absence of the Wnt signal,
nuclear Tcf acts as a repressor of Wnt target genes [126]
by forming a complex with Groucho [21]. The repressive
effect of Groucho has been shown to be mediated by in-
teractions with HDACs [127]. β-catenin can convert Tcf
into a transcriptional activator of the same genes that are
repressed by Tcf alone (reviewed in [128]). It has been
shown that sodium butyrate and Trichostatin A (TSA),
inducers of G0-G1 cell cycle arrest and apoptosis in the
SW620 colonic carcinoma cell line, up-regulate Tcf ac-
tivity. Sodium butyrate and TSA are inhibitors of HDAC
activity independent of their effects on β-catenin/Tcf sig-
naling, and by altering chromatin structure they may ren-
der loci accessible to Tcf or other transcription factors
[129]. This is in agreement with data shown by Ohira
et al who have shown induction of the Wnt signaling
pathway target gene, E-cadherin, by HDAC inhibition
with TSA or GSK3β inhibition with LiCl and an addi-
tive or synergistic effect on E-cadherin expression with
both inhibitors [130]. These studies suggest that HDACs
help to repress the Tcf activity. HDAC inhibitors such
as butyrate and TSA, block this repression resulting in a
reduction of the threshold necessary to activate Tcf tran-
scription. Tight regulation of transcription imposed by
HDACs and HATs appears to be crucial for normal activ-
ity.WhenthisregulationislostthroughHDACinhibitors,
treated cells will go into cell cycle arrest and apoptosis.
In Drosophila, Tcf has been shown to interact with CBP
(CREB binding protein, histone acetylase), thereby re-
pressing gene transcription when Wnt signaling is inac-
tive [131]. In mammalian cells, CBP/P300 can also act
as a co-activator of β-catenin/Tcf [20]. This might also
turn out to be one of the mechanisms by which HDAC in-
hibitors function. Through inhibiting HDAC, CBP/P300
will no longer be able to function as a co-activator, and
possibly even repress the β-catenin/Tcf signal. A recent
study by Zhu et al. showed that loss of the APC tumor
suppressor induced HDAC2 expression in solid tumors
[125]. This upregulation was not directly through the β-
catenin pathway, but most likely indirectly through up-
regulation of c-Myc which is a target gene of the Wnt
pathway. HDAC2 is required for and sufﬁcient on its own
to prevent apoptosis of colonic cancer cells, and interfer-
ence with HDAC2 by valproic acid largely diminished
adenoma formation in APC min mice.
GSK3β inhibitors can be divided into several groups:
(1) the non-selective GSK3β inhibitors, such as lithium
and valproic acid; (2) the ATP-competitive inhibitors,
which can be divided in several classes according to
their chemical structure [132]; and (3) the non-ATP-
competitors such as small thiadiazolidinones derivatives,
the ﬁrst non-ATP competitive GSK3β inhibitors reported
to date [133]. A detailed description of the different
GSK3β inhibitors is beyond the scope of this review,
for more information on the different classes, we refer to
[134–136]. Only Lithium and Valproic acid are discussed
here because many studies have demonstrated their effect
on the Wnt signaling pathway.
Lithium has been shown to be a non-speciﬁc reversible
inhibitor of GSK3β with an IC50 value of 2 mM [137].
Recently, it was reported that the response to lithium
occurs via two levels of inhibition: a rapid, direct in-
hibition of GSK3β by competing for Mg2+, followed
by the inactivation of Protein Phosphatase 1 and sub-
sequent increased inhibitory phosphorylation of GSK3β
[138]. These two inhibitory actions following exposure
to lithium probably act together in vivo to achieve an in-
creased inhibition of GSK3β [139]. Signal transduction
systems known to be perturbed by lithium involve phos-
phoinositide (PI) turnover, activation of the Wnt pathway
via inhibition of GSK3β, and a growth factor-induced,
Akt-mediated signal that promotes cell survival. These
pathways, acting in synergy, probably lead to the ampli-
ﬁcation of the lithium signal. Because of the functions
of GSK3β in many different signaling pathways and dis-
eases (diabetes, Alzheimer’s disease, mood disorders, in-
ﬂammatory signaling and cancer), it is likely that lithium
can have therapeutic effects in all these diseases, but the
possibility of unwanted side-effects will also increase.
Valproic acid (VPA, 2-propylpentanoic acid) like
lithium, is an established drug. During the past years,
it has become evident that VPA is also associated with
anti-cancer activity. VPA not only suppresses tumor
growth and metastasis, but also induces tumor differen-
tiation in vitro and in vivo. Several mechanisms of ac-271
tion might be relevant for the biological activity of VPA:
(1) VPA increases the DNA binding ability of activating
protein-1 (AP-1) transcription factor, and the expression
of genes regulated by the extracellular-regulated kinase
(ERK)-AP-1 pathway; (2) VPA downregulates protein
kinase C (PKC) activity; (3) VPA inhibits GSK3β, a neg-
ative regulator of the Wnt signaling pathway; (4) VPA
activates the peroxisome proliferator-activated receptors
PPARγ and δ; and (5) VPA blocks HDAC [140]. VPA
may thus exert its function on Wnt signaling through in-
hibitionofGSK3β and/orinhibitionofHDAC[141,142].
Gleevec
R  , (Glivec, imatinib mesylate, STI571),
although originally identiﬁed as platelet derived growth
factor (PDGF) receptor inhibitor, and developed as an
inhibitor of the constitutively active Bcr-Abl kinase,
is also able to inhibit the c-kit tyrosine kinase. It is
conceivable that other tyrosine kinases may also serve
as possible cellular targets of Gleevec, especially when
higher concentrations of Gleevec are used [143]. Gleevec
has recently been approved for the treatment of chronic
myeloid leukemia and gastrointestinal tumors [143].
β-catenin is a tyrosine phosphorylated protein and some
growth factors (such as HGF, IGF-1 and IGF-2) may play
ar o l ei nr e g u l a t i n gβ-catenin signaling activity. Gleevec
has been shown to effectively inhibit the constitutive
activity of β-catenin signaling in human colon cancer
cells (HCT-116 and SW480) as well as in Wnt1 induced
activation of β-catenin signaling in different cell lines
[143]. Furthermore, Gleevec was shown to effectively
suppress the proliferation of these human colon cancer
cells. The current prevailing hypothesis is that tyrosine
phosphorylation of the β-catenin protein would result in
decreased association with E-cadherin, leading to the dis-
ruption of junctional assembly and an increased tendency
forcancercellstobecomeinvasiveandmetastasize[143].
Tyrosine phosphorylation may thus play an important
role in regulating β-catenin signaling activity, and inhibi-
tion of this signaling pathway by Gleevec may be further
explored as an important target for alternative/adjuvant
treatments for different types of cancer.
Flavonoids comprise the most common group of plant
polyphenols and provide much of the ﬂavor and color
to fruits and vegetables [144]. More than 5000 differ-
ent ﬂavonoids have been described, and they are di-
vided into 6 subclasses. Yang and colleagues have re-
cently published several articles on the effect of different
ﬂavonoids, such as quercetin, naringenin and ﬂavanone,
on β-catenin/Tcf signaling using in vitro assays [145—
147]. Their data suggest that the different ﬂavonoids
testedinhibitβ-catenin/Tcf signalingefﬁcientlyalthough
a common mechanism by which ﬂavonoids inhibit Tcf
activity remains to be established. The large amount of
studies on ﬂavonoids exempliﬁes the interest in the bio-
logical properties of natural products as a means to iden-
tify novel small molecular weight compounds that could
have potential as therapeutic. Because different studies
have reported contrasting observations ranging from a
protective effect of ﬂavonoid consumption in cardiovas-
cular disease and cancer to potential harm, it would be
imperative to have a thorough understanding of the dif-
ferent mechanisms of action whereby ﬂavonoids might
act in different tumor and normal cell types. In vitro stud-
ies such as those reported by Park et al. are important
in the determination of the potential of a compound as
a chemotherapeutic agent. This group has recently also
shown that ionomycin inhibits β-catenin/Tcf signaling in
colon cancer cells [148].
Drug design strategies for the Wnt−dependent signaling
pathways in cancer
Many components of the Wnt-dependent signaling path-
ways may represent targets for future drug discovery ef-
forts. As previously described, the initial step in Wnt-
dependent signaling is the interaction between Wnt and
Fzd. Cancer cellgrowthmaybeinhibitedbyanagent that
would selectively inhibit the binding of the Wnt protein
with its Fzd receptor or which would upregulate the ex-
pressionofendogenousantagonistssuchassFRP,WIF-1,
Cerberus or DKK. This agent could be an antibody that
speciﬁcally binds to a Wnt protein, or a Fzd receptor to
disrupt the binding between ligand and receptor. Ithas re-
cently been demonstrated that anti-Wnt2 antibodies can
induce apoptosis in human cancer cells [53, 54]. These
antibodies showed no detectable effect on normal cell
lines, suggesting anti-Wnt2 antibody could speciﬁcally
induce apoptosis in cancer cells, whilst sparing normal
cells. Anti-Wnt antibodies may not only directly induce
apoptosis in cancer cells that overexpress Wnt proteins,
but also counter potential drug resistance by restoring the
normal apoptotic machinery in these tumor cells [52]. A
potential hurdle that antibody-based therapies could face
is the epitope accessibility in the tumor.
Although ligand-receptor interactions are heavily tar-
geted in drug discovery, the ligand-receptor interaction
in the Wnt signaling pathway is not as straightforward as
for other pathways. Of the entire Wnt signaling pathway,
least is known about the ligand-receptor interaction. One
major barrier hampering the understanding of this has
been the difﬁculty in obtaining soluble and biologically
active Wnt proteins. With the recent success by Willert
etal.inpurifyingWnt3a[149],andelucidatingthechem-
ical basis for the uncooperative property of Wnt proteins,
this hurdle has been overcome. The second problem
is the speciﬁcity of Wnt/Fzd interactions. As indicated
previously, the Wnt family consists of at least 19 mem-
bers(http://www.stanford.edu/∼rnusse/wntwindow.html)
who all share a conserved pattern of 23 or 24272
cysteine residues, several asparagine-linked glyco-
sylation sites and a length of 350 to 400 amino
acids [150]. The Fzd family consists of 10 members
(http://www.stanford.edu/∼rnusse/wntwindow.html).
Structurally, Fzd receptors are similar to other seven-pass
transmembrane proteins such as G-protein coupled
receptors (GPCRs), but the actual signaling through a
G-protein has only been observed in a few cases. Direct
binding with full-length Fzd has been demonstrated for
only a few Wnt proteins, including Wg and XWnt8
[151, 152]. These in vitro binding experiments showed
that a single Wnt can bind to several Fzd proteins,
including homologous members from a different species.
A more comprehensive assessment of the interactions
between various Wnt/Fzd pairs remains to be conducted.
The promiscuous binding pattern observed with some
Wnt and Fzd members raises the possibility that there
may be considerable redundancy in ligand-receptor
interactions [151–153]. The fact that Fzd receptors are
putative GPCRs makes it a more interesting target. It
has been estimated that 50% of all modern drugs and
almost one-quarter of the top-selling drugs in the year
2000 modulated GPCR activity [154]. This reﬂects
the expertise many pharmaceutical companies have on
GPCR drug design. However, despite the past success
of drug development on GPCRs, current efforts to bring
further classes of GPCR-targeted drugs through the
pipeline are proving less productive than might have
been predicted. This is in spite of the accumulated
knowledge on GPCRs. This has led to a change in the
way drug discovery is being approached. The emphasis
of GPCR-directed drug discovery is shifting from a
traditional focus on biogenic monoamine receptors,
which have natural ligands that are readily amenable to
chemical modiﬁcation to produce lead compounds, to a
more recent focus on peptide-activated receptors, which
presentanentirelydifferenttypeofsyntheticchallengeto
the drug discovery community. The Wnt/Fzd interaction
is one such example of a peptide-receptor interaction,
and thus may be a reason for avoiding this interaction as
a drug target, until more is known about these types of
interactions. The third problem is the co-receptor. The
β-catenin pathway requires an additional single-pass
transmembrane protein, known as LRP5 and LRP6 from
the low-density-lipoprotein (LDL) receptor family, to
function as an obligate co-receptor for transducing the
Wnt signal [9–11]. This adds another level of complexity
as different receptor and co-receptor combinations can
result in the transduction of signals down different
pathways. LRPs are single transmembrane proteins that
contain epidermal growth factor like repeats and three
LDL-receptor type Q repeats in their extracellular region
[155]. Intracellularly, these proteins contain a proline-
rich region that are predicted to bind to SH3 domain
containing proteins. It appears that these co-receptors
associate with Fzd in a Wnt-dependent fashion [10].
It is not yet clear how these complexes are organized;
they may be heterotrimeric complexes of LRP, Fzd
and Wnt, or heterodimeric complexes of just Fzd and
LRP. It may also be that these proteins are important
intracellularly, bridging Fzd and Dvl, or Fzd and other
signaling molecules such as SH3 domain containing
proteins. The function of the LRP co-receptors appears to
be tightly connected to their Fzd/Wnt-related functions
since knocking out these proteins mimics a combination
of Wnt knockout phenotypes [44]. These observations
make the Wnt/Fzd interaction a very difﬁcult target for
small molecule inhibitors, additional to the fact that
peptide interactions are inherently more difﬁcult targets
to modulate.
Following activation of the Fzd receptor, the unequiv-
ocal identiﬁcation of the downstream signaling mecha-
nism remains to be unraveled. One hypothetical pathway
leads to Dvl activation. Data suggest that Dvl proteins
organize dynamic, pathway-speciﬁc subcellular signal-
ing complexes that ensure correct information routing,
signal ampliﬁcation, and dynamic control through feed-
back regulation [156]. Interrupting the Fzd-Dvl interac-
tioncouldserveasapowerfultooltodissectthemolecular
mechanism underlying the Wnt pathways. Furthermore,
it could interfere with speciﬁc Wnt signaling events that
contribute to cancer and other human diseases.
There is evidence that the multiprotein β-catenin de-
struction complex could turn out to be a relatively good
drug target. Of the components of the complex (Axin,
APC, β-catenin and GSK3β), GSK3β is the best vali-
dated target, due to its implication in the pathophysiol-
ogy of numerous other diseases, including Alzheimer’s
disease, diabetes, and bipolar disorder [157, 158]. Origi-
nally identiﬁed as a modulator of glycogen metabolism,
GSK3 is now understood to play an important role in a
varietyofpathwaysincludinginitiationofproteinsynthe-
sis, cell proliferation, cell differentiation, apoptosis, and
is essential in embryonic development as a component
of the Wnt signaling cascade. GSK3 can be considered
as a target for both metabolic and neurological disorders.
However, a major concern is that since this protein is
involved in so many pathways and diseases, compounds
targeting this protein for its function in one pathway (and
linked disease) will alter its function in another pathway
and potentially give rise to serious side effects (on-target
side effects). For instance, lithium described as a non-
selectiveGSK3β inhibitorisusedfortreatmentofbipolar
disorder as well as in cancer research, to activate the Wnt
signaling pathway as a model for carcinogenesis. It is
thus of considerable importance to determine if GSK3β
inhibitors also have a tumorigenic effect. Gould et al.
recently investigated the effects of lithium in a murine273
model predisposed to the formation of tumors due to ac-
tivation of the Wnt pathway (the APC multiple intestinal
neoplasia(min)mouse)[159].Theyfoundthat60daysof
lithium treatment did not produce a signiﬁcant increase
in the number of tumors in these genetically predisposed
mice,itonlyresultedinamodestoverallincreaseinthetu-
mor size [159]. These results suggest that lithium, which
has been prescribed for more than 50 years, and by ex-
tension perhaps other inhibitors of GSK3, pose a low risk
for the development of cancers. This is entirely consis-
tentwiththeavailableepidemiologicalevidencethatlong
term lithium therapy does not increase cancer morbidity
ormortality.Furthermore,othermechanismsindependent
of phosphorylation by GSK3 can contribute to β-catenin
degradationindicatingaredundancyinmechanismslead-
ing to β-catenin degradation. Recent crystal structures,
including the active (phosphorylated Tyr-216) form of
GSK3β, provided a wealth of structural information and
greater understanding of GSK3’s unique regulation and
substrate speciﬁcity [160].
As stated previously, activation of β-catenin is a crit-
ical step in the pathogenesis of many common human
cancers and is the initiating event in adenocarcinoma of
the colon [161]. Oncogenes such as β-catenin represent
(in theory) extremely attractive molecular targets for the
development of anticancer compounds as speciﬁc phar-
macological inhibition of activated β-catenin might re-
verse the tumorigenic properties of human cancer cells
and therefore form the basis of an effective anticancer
strategy [161]. Recently, proof of principle was shown
when small interfering RNAs (siRNAs) directed against
β-catenininhibitedtheinvitroandinvivogrowthofcolon
cancer cells. These siRNAs ultimately may have the po-
tentialasatherapeuticmodalitytotreatcancer[162,163].
β-cateninhasdiversefunctionsasanessentialcomponent
of intercellular junctions and the Wnt signaling pathway
and has therefore numerous different binding partners
(Figure 2).
The interaction of β-catenin with Lef/Tcf transcrip-
tion factors is seen as one of the crucial events. Over-
expression of dominant negative Tcf4 in colorectal tumor
cells causes cells to arrest in the G1 phase of the cell cy-
cle supporting the relevance of Tcf4 in colorectal tumor
cell proliferation [164]. Several studies have shown that
inhibition of the initiating transforming event in colorec-
tal cancer cell lines, i.e., the inappropriate formation of a
β-catenin/Tcf complex, drives these cells out of the cy-
cle [164]. Tcf4 inhibition induced colorectal cancer cells
to differentiate into a villus epithelial phenotype, essen-
tially completing their life cycle after many years delay
[165]. Tcf4 has recently been identiﬁed as a transcrip-
tional target of p53 signaling. Induction of p53 leads to a
reduction of Tcf4 mRNA and protein [166], and thus acts
to decrease the Wnt/β-catenin signaling activity. Hence,
the accumulated data make a strong argument to consider
the β-catenin/Tcf4 complex a promising target for ther-
apeutic intervention in cancer. Small molecular weight
inhibitors of this interaction might therefore be expected
to have anti-tumorigenic effects.
Lepourcelet et al. have explored high-throughput
screening of compound libraries in search for small
molecule inhibitors of the Wnt cascade [167]. Out of
approximately 7,000 natural compounds, 8 displayed
reproducible and dose-dependent inhibition of the
protein-protein interaction between β-catenin and Tcf4
in an immunoenzymatic assay with IC50 values lower
than 10 µM (Figure 3). Six compounds were evaluated in
a range of in vitro secondary assays such as reporter gene
activation, expression analysis, cell proliferation, and
Xenopus duplication assay. Three compounds (PKF115-
584, CGP049090, and PKF222-815), with the same
chemical core structure, scored consistently in the differ-
ent assays (surface plasmon resonance, reporter gene as-
says, GST-pulldown assay, electrophoretic mobility shift
assay) used to conﬁrm the antagonistic properties of the
compounds. Initial reports from Lepourcelet et al. show
that the classical approach of high throughput screening
ina cell-free assay can yield protein interaction inhibitors
that retain their effects when tested in cell-based assays
[167]. A search of the patent literature indicates that
Figure 2. Interaction sites for binding partners of β-catenin (from http://www.stanford.edu/∼rnusse/wntwindow.html).274
several other groups are studying compounds and meth-
ods for modulating β-catenin mediated gene expression.
For instance, Blaschuk et al. described several peptide
sequences capable of affecting the interaction between
β-catenin and transcription factors [168], while Moll
et al. identiﬁed a compound which is able to interact with
β-catenin/Tcf4 [169]. The difference in binding afﬁnity
of Tcf4 to β-catenin in the presence of an inhibitor was
determined through Isothermal Titration µ-Calorimetry
(ITC). The identiﬁed compound reduced Tcf4 afﬁnity
for β-catenin about 10-fold. NMR screening, which is
particularlysuitedfortheidentiﬁcationofprotein-protein
interaction antagonists conﬁrmed that the compound is
an antagonist of the β-catenin/Tcf4 interaction.
More recently, a patent and subsequent publication
by Kahn et al., disclosed the preparation and biological
evaluation of a series of compounds able to block the β-
catenin/Tcf4 transcriptional pathway by inhibiting cyclic
AMP response element-binding protein (CBP) (Figure 4)
[70, 171]. CBP or its closely related homolog p300 were
initially identiﬁed in protein interaction assays, ﬁrst
through their association with the transcription factor
CREB [172] and later through their interaction with the
adenoviral-transforming protein E1A [173]. CBP had the
potential to participate in a variety of cellular functions
including transcriptional coactivator function [174].
CBP/p300 potentiates β-catenin mediated activation
[20]. β-catenin interacts directly with the CREB-binding
domain of CBP and β-catenin synergizes with CBP to
stimulate the transcriptional activation of β-catenin/Tcf4
[175]. The compound (ICG-001; Figure 4) described by
Kahn et al. showed speciﬁc afﬁnity and inhibition of
CBP, and proved effective in preventing CBP-mediated
transcriptional activation and β-catenin/Tcf4 transcrip-
tion in luciferase reporter gene assays. ICG-001 induced
apoptosis in SW480 colon cancer cells in a concentration
dependent manner, but not in normal colonic epithelial
cells and inhibited the growth of SW480 cells with
an IC50 value of 8.07 µM. They also demonstrated
that ICG-001 was efﬁcacious in both the Min mouse
and nude mouse SW620 xenograft models of cancer
[170]. Mapping studies demonstrated that the interacting
domains of both CBP and p300 with the C-terminus of
β-catenin reside within the N-terminal 110 residues of
the co-activators. Interestingly, this region also contains
the CBP/p300-binding site for retinoic acid (RA)
receptors, RXR/RAR [176]. It has been shown that RA
treatment inhibits β-catenin/Tcf-mediated transcription
[177].
Ultimately, the above described compounds could be-
come novel anticancer drugs. These compounds certainly
have considerable potential as tools for the investiga-
tion of β-catenin dependent cellular pathways. They also
clearly show the feasibility of targeting protein-protein
Figure 3. Lead structures for Wnt signaling pathway inhibitors.
Figure 4. Chemical structure of ICG-001.
interactions in cancer drug discovery. The β-catenin/Tcf




The design of compounds targeting the β-catenin/Tcf
interaction depends on a detailed understanding of the in-
teractions of β-catenin with its other interaction partners.
The interaction between Tcf transcription factors and β-275
catenin requires a minimal N-terminal Tcf fragment and
the central domain of 12 armadillo repeats in β-catenin
[179, 180]. Disrupting the E-cadherin binding has been
implicated in the transition form adenoma to carcinoma,
suggesting that the adhesive role of β-catenin is likely
to be crucial for suppressing tumor growth and metas-
tasis. Disrupting the interaction of β-catenin with APC
or Axin would also have undesirable consequences, as it
would lead to a larger pool of free β-catenin by inhibiting
β-catenin degradation. Increasing concentrations of the
drug would then be required to inhibit the β-catenin/Tcf
interaction. The compounds shown in Figure 3 that have
been described as β-catenin/Tcf4 antagonists also dis-
rupt cellular β-catenin/APC complexes [167] supporting
thespeculationthatpharmacological interferencewithβ-
catenin complexes may be inherently unselective [180–
182]. The β-catenin/Tcf complex is an enticing target for
rational design of cancer therapeutics, but the promis-
cuity of β-catenin makes it clear that this strategy will
not be easy. More detailed thermodynamic and structural
data on ligand recognition by β-catenin and insights ob-
tained from the crystal structures of β-catenin/Tcf [183,
184] and alternative protein complexes should aid this
process. But the results by Emami et al. have shown that
targeting alternative mechanisms to inhibit a subset of
β-catenin/Tcf-mediated transcription can enhance the se-
lectivity of the compounds [170].
GiventhattheWntsignalingpathwayisimplicatedina
substantialnumberofdiseases,andgiventhatanumberof
mutations lead to the activation of this pathway and can-
cer in several tissues, there is a clear need for drugs that
attenuatethenuclearfunctionsofβ-catenin.Futuredevel-
opment of both peptide and non-peptide based inhibitors
of components of the Wnt signaling pathway, combined
with further elucidation of mechanisms of action will
undoubtedly result in the generation of more potent and
speciﬁcinhibitorsofWntsignaling.Theseinhibitorsmay
provide signiﬁcant therapeutic beneﬁt against a variety of
humandiseasesinwhichtheWntsignalingpathwayplays
an important pathological role.
In conclusion, we have discussed the many opportuni-
ties that lie within the Wnt signaling pathway to be used
as targets in oncology drug discovery. In addition, the
small molecule inhibitors of the Wnt signaling pathway
that have been discussed here could clear the path for
large scale screens to discover speciﬁc inhibitors that
target components or mechanisms in the Wnt-dependent
signaling pathways.
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